Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Papillomavirus Vaccines 2Imiquimod 2GX-188 vaccine 2Celecoxib 24,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone 2poly(gamma-glutamic acid) 1pembrolizumab 1nimotuzumab 1epigallocatechin gallate 1artesunic acid 1artemisinin 1Sutures 1Progesterone 1Pemetrexed 1Omeprazole 1Ointments 1Ocoxin 1Nelfinavir 1Lighting 1Indomethacin 1IRX 2 1Hepatitis B Vaccines 1Geritol 1GPI0100 1Folic Acid 1Eflornithine 1Cyclophosphamide 1Conization 1Cisplatin 1Chemoprevention 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Dysplasia × Hepatitis B Vaccines × Clear all
NCT01356823 2016-01-05

Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Xiamen University

Phase 2 Completed
1,600 enrolled
Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡